FIRMAGON 240
Total Payments
$394,398
Transactions
8
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2018 | $232,869 | 6 | 0 |
| 2017 | $161,529 | 2 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $394,398 | 8 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer | Ferring Pharmaceuticals Inc. | $228,820 | 0 |
| A Phase II Study of Docetaxel Before Medical Castration with Degarelix in Patients with Newly Diagnosed Metastatic Prostatic Adenocarcinoma | Ferring Pharmaceuticals Inc. | $135,682 | 0 |
| Nivolumab and BMS-986253 for Hormone-Sensitive Prostate Cancer MAGIC-8 | Ferring Pharmaceuticals Inc. | $29,895 | 0 |
Top Doctors Receiving Payments for FIRMAGON 240
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Charleston, SC | $394,398 | 8 |
Ad
Manufacturing Companies
- Ferring Pharmaceuticals Inc. $394,398
Product Information
- Type Drug
- Total Payments $394,398
- Total Doctors 0
- Transactions 8
About FIRMAGON 240
FIRMAGON 240 is a drug associated with $394,398 in payments to 0 healthcare providers, recorded across 8 transactions in the CMS Open Payments database. The primary manufacturer is Ferring Pharmaceuticals Inc..
Payment data is available from 2017 to 2018. In 2018, $232,869 was paid across 6 transactions to 0 doctors.
The most common payment nature for FIRMAGON 240 is "Unspecified" ($394,398, 100.0% of total).
FIRMAGON 240 is associated with 3 research studies, including "Phase III Randomized Trial Comparing Short Course Androgen Deprivation Therapy and Ultra-Hypofractionated SBRT Versus SBRT Alone For Intermediate Prostate Cancer" ($228,820).